A website dedicated to the world of M&A – transactions, ideas, insights and other relevant M&A-related resources.
With Abbott’s () $25Bn bid for St. Jude Medical () made official on Thursday, and with this being only yet one more multi-billion-Dollar bid in the space this year, one is left wondering how much longer will this sector be able to…
Teva Pharmaceuticals () is no less than the world’s #1 drug company in the Generics segment. For those who still wonder, Generics, in short, are drugs made by plants others than those having developed – and patented – the active ingredient. New…
Today’s Pharma big deal is in the compounded drug segment. AmerisourceBergen, not at all shy when it comes to acquisitions, announced its acquisition of PharMEDium Healthcare Holdings from Private Equity Fund Clayton, Dubilier & Rice for a mere $2.575 Billion. More than a good exit for…
As discussed here previously, the FTC approved Endo’s acquisition of Par Pharmaceuticals last Friday, making the $8Bn deal official. The acquisition is aligned with Endo’s strategy and makes a lot of sense in terms of amplifying the company’s product portfolio, presence in…
I love the Pharma space, M&A-wise. It’s a huge market with many players and with a bunch of firms thriving in executing roll-up acquisition strategies. The other reason why I love the Pharma space is for the readily available information in the space….